INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2016. The put-call ratio across all filers is 0.81 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,237,162 | -67.4% | 42,948 | -60.4% | 0.01% | -61.5% |
Q2 2023 | $6,866,926 | -95.5% | 108,448 | -95.7% | 0.01% | -95.5% |
Q1 2022 | $154,185,000 | +23.3% | 2,519,764 | +5.5% | 0.29% | +26.4% |
Q4 2021 | $125,003,000 | +46.1% | 2,388,294 | +4.0% | 0.23% | -34.9% |
Q3 2021 | $85,582,000 | -24.3% | 2,295,634 | -17.2% | 0.36% | -30.7% |
Q2 2021 | $113,125,000 | +17.6% | 2,771,304 | -2.2% | 0.51% | +16.1% |
Q1 2021 | $96,174,000 | +0.3% | 2,834,460 | -6.0% | 0.44% | -15.2% |
Q4 2020 | $95,900,000 | +24.1% | 3,015,732 | +0.1% | 0.52% | +5.1% |
Q3 2020 | $77,298,000 | +128.5% | 3,012,377 | +128.6% | 0.50% | +108.9% |
Q2 2020 | $33,831,000 | +221.4% | 1,317,930 | +92.5% | 0.24% | +125.7% |
Q1 2020 | $10,526,000 | +2662.7% | 684,778 | +6873.3% | 0.10% | +3400.0% |
Q2 2016 | $381,000 | -69.4% | 9,820 | -57.6% | 0.00% | -75.0% |
Q4 2015 | $1,245,000 | +66.0% | 23,148 | +23.5% | 0.01% | +33.3% |
Q3 2015 | $750,000 | – | 18,738 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |